


ERSTE STOCK BIOTEC VT

Biotechnology stocks with a focus on the US market

ISIN: AT0000A0XYP0

Overview

2024/03/19		
NAV		
12,931.8300		
Difference		0.04% (4.54)
General attributes		
Fund type	Equity Funds	
Investment company	Erste Asset Management GmbH	
Currency	CZK	
Type	VT	
Begin of subscription period	-	
Inception	2000/04/17	
Licenced in	AT,CZ	
Duration of fund	open end	
Distribution	06/15	
Total assets	249,329,515.76 EUR	
Fiscal year	03/15 - 03/14	
Initial charge	3.00%	
Management fee	1.80%	
Ongoing charges	2.06%	
Minimum investment	According to offer	
Account number	-	
Recommended holding period	At least 6 years	
Investor experience	-	
Investor tolerance	5 (scale 1-7)	
Disclosure Regulation	Article 8	

Initial charge represents a % of the value of the current fund share unit price and is charged once upon making the investment. Management Fee and Ongoing Charges represent costs paid from the assets of the mutual fund on an annual basis (per annum).

Performance goal and investment strategy

The ERSTE STOCK BIOTEC invests primarily in companies in the developed markets from the field of biotechnology. The fund's investment process is based on fundamental business analysis. The majority of companies in this area can be found in the United States. As a result, Pacific and European equities tend to play a subordinated role in the fund. A hedge against foreign currency risks is generally not provided, but is possible.

Performance (2024/02/29)							
Period	YTD	6m	1Y	3Y	5Y	10Y	since inc.
			(% p a)	(% p a)	(% p a)	(% p a)	(% p a)
Perf	8.13	-	16.98	-0.78	0.36	4.59	10.53

Annual performance in % (2024/02/29)					
Period	2019	2020	2021	2022	2023
Perf	32.21	14.45	7.89	-4.73	3.72

Statistical figures (2024/02/29)	
Sharpe Ratio	-
Volatility in %	16.40

Minimum & maximum performance in % p.a. (2024/02/29)		
1Y	117.38	
		-51.90
3Y	52.56	
		-22.95
5Y	42.14	
		-9.64
10Y	21.55	
		-4.24

Upozornění na riziko podle rakouského zákona o investičních fondech 2011

Unless explicitly noted otherwise, performance figures for periods of less than ten years always start from the launch of the fund. Performance figures for periods of less than 12 months in particular are not indicative of a fund's development due to their short-term nature.

ERSTE STOCK BIOTEC may exhibit increased volatility due to the composition of its portfolio: i.e. the unit value can be subject to significant fluctuations both upwards and downwards within short periods of time.

Top holdings (2024/02/29)			
ISIN	Name	Currency	%FA
-	REGENERON PHARMAC.DL-,001	-	8.94
-	VERTEX PHARMAC. DL-,01	-	8.17
-	GILEAD SCIENCES DL-,001	-	6.98
-	ASTRAZENECA DL-,25 SP.ADR	-	6.28
-	AMGEN INC. DL-,0001	-	4.21
-	BIOGEN INC. DL -,0005	-	4.20
-	VIKING THERAPEUT.DL -,005	-	2.80
-	BIOMARIN PHAR. DL-,001	-	2.78
-	ARGENS SE SP.ADR/1 -,10	-	2.47
-	MADRIGAL PHARMAC. DL-,01	-	2.30

Holdings by country (2024/02/29)	
	86.76 % United States of America
	7.01 % United Kingdom
	2.81 % Netherlands
	1.03 % Denmark
	1.03 % Canada

Holdings by currency (2024/02/29)	
	99.32 % USD
	0.68 % EUR

Percentage holdings by sector (2024/02/29)	
<div></div>	83.47 % Biotechnology
<div></div>	11.73 % Pharmaceuticals
<div></div>	4.22 % Life Sciences Tools & Services
<div></div>	0.59 % Health Care Services

Disclaimer

The full names of the open-ended mutual funds and complete product information are provided in the statutes (prospectuses) of the funds. The information stated herein is of the nature of a promotional message. The information stated in this message is not an investment recommendation or investment advice since it does not take into account the specific situation of specific investors. The value of the financial instruments may rise and fall, while there is no guarantee of a return on the originally invested amount. Past performance is no guarantee of the same performance in a future period. A visitor to this website may be outside the target market of the financial instruments stated herein. We recommend that you consult your specific investment plan with an expert advisor who will verify that the planned investment will be commensurate with your knowledge and experience, that it will be in accordance with your needs, characteristics and goals, financial circumstances or relation to risk, and will familiarise you with all possible risks of a specific investment opportunity.